微信小陈
微信小章
产品简介
购买须知
| 产品名称： | CTLA4Ig |
|---|---|
| 商品货号： | TS194870 |
| Designations： | CTLA4Ig |
| GenBank Number： | I13253 M27286 M27287 |
| Species： | Homo sapiens, human |
| Depositors： | Bristol-Myers Squibb Co., P Linsley, Bristol-Myers Squibb Co. |
| Applications： | in another host, produces protein cytotoxic T-lymphocyte-associated protein 4 - IgCgamma1 chimera |
| Vector： | Construct size (kb): 5.199999809265137 |
| Insert： | DNA: cDNA Insert lengths(kb): 0.4600000083446503 Tissue: HTLV II-associated leukemia cell line H38 Gene product: cytotoxic T-lymphocyte-associated protein 4(cytotoxic T-lymphocyte-associated serine esterase 4) CTLA4 Alleles: A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17 Target Gene: cytotoxic T-lymphocyte-associated protein 4 - IgCgamma1 chimera |
| Insert Size (kb)： | 0.460 |
| Media： | ATCC® Medium 1890: LB medium (ATCC medium 1065) with 12 mcg/ml tetracycline and 100 mcg/ml ampicillin |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Shipping Information： | Distributed: freeze-dried |
| Comments： | Restriction digests of the clone give the following sizes (kb): HindIII/XbaI--4.0, 1.2; HindIII--5.2; XbaI--5.2. Restriction digests of the clone give the following sizes (kb): HindIII--5.2; HindIII/XbaI--4.0, 1.2; PstI--5.2; XbaI--5.2; XhoI--5.2. The Ig hinge cysteines were mutated to serine residues during construction to prevent intrachain disulfide bonding. Expresses a soluble derivative of CTLA4, consisting of the oncostatin M signal sequence and partial exon 2 sequence, the extracellular portion of CTLA4, and the hinge, CH2 and CH3 portions of Ig Cgamma1. A stable CHO transfectant expressing this construct is available as CRL-10762. |
| References： | Linsley PS. Chimeric CTLA4 receptor and methods for its use. US Patent 5,434,131 dated Jul 18 1995 Linsley PS, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173: 721-730, 1991. PubMed: 1847722 |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |